$24.24
0.86% yesterday
Nasdaq, Jun 13, 10:02 pm CET
ISIN
US6951271005
Symbol
PCRX

Pacira Pharmaceuticals, Inc. Stock price

$24.24
+0.84 3.59% 1M
+4.38 22.05% 6M
+5.40 28.66% YTD
-4.13 14.56% 1Y
-19.17 44.16% 5Y
-54.32 69.14% 10Y
+17.22 245.30% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.21 0.86%
ISIN
US6951271005
Symbol
PCRX
Sector
Industry

Key metrics

Market capitalization $1.12b
Enterprise Value $1.21b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 7.60
EV/Sales (TTM) EV/Sales 1.39
P/S ratio (TTM) P/S ratio 1.29
P/B ratio (TTM) P/B ratio 1.40
Revenue growth (TTM) Revenue growth 27.59%
Revenue (TTM) Revenue $869.89m
EBIT (operating result TTM) EBIT $105.75m
Free Cash Flow (TTM) Free Cash Flow $159.40m
Cash position $493.63m
EPS (TTM) EPS $-2.06
P/E forward 16.86
P/S forward 1.51
EV/Sales forward 1.63
Short interest 17.84%
Show more

Is Pacira Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Pacira Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:

3x Buy
43%
3x Hold
43%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Pacira Pharmaceuticals, Inc. forecast:

Buy
43%
Hold
43%
Sell
14%

Financial data from Pacira Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
870 870
28% 28%
100%
- Direct Costs 205 205
12% 12%
24%
665 665
33% 33%
76%
- Selling and Administrative Expenses 381 381
41% 41%
44%
- Research and Development Expense 107 107
38% 38%
12%
177 177
18% 18%
20%
- Depreciation and Amortization 72 72
25% 25%
8%
EBIT (Operating Income) EBIT 106 106
13% 13%
12%
Net Profit -95 -95
234% 234%
-11%

In millions USD.

Don't miss a Thing! We will send you all news about Pacira Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pacira Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
BRISBANE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on June 3, 2025 to 19 new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement...
Neutral
GlobeNewsWire
about one month ago
BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:
Neutral
PRNewsWire
about one month ago
SAN DIEGO , May 13, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX). Investors who purchased shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) prior to August 2023 and continue to hold any of those NASDAQ: PCRX shares also have certain options and contact the Shareholders Foundation...
More Pacira Pharmaceuticals, Inc. News

Company Profile

Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Head office United States
CEO Frank Lee
Employees 789
Founded 2006
Website www.pacira.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today